Intraretinal leakage and oxidation of LDL in diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 6, 2008, Pages 2679-2685

  Wu, Mingyuan ^a   Chen, Ying ^a   Wilson, Kenneth ^a   Chirindel, Alin ^a   Ihnat, Michael A ^b   Yu, Yongxin ^a   Boulton, Michael E ^c   Szweda, Luke I ^d   Ma, Jian Xing ^a,b   Lyons, Timothy J ^a,e  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; CASPASE; LOW DENSITY LIPOPROTEIN; CASPASE 3; CASPASE 7; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL CULTURE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE SEVERITY; ENZYME ACTIVATION; GLYCATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MITOCHONDRION; NICK END LABELING; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PERICYTE; PRIORITY JOURNAL; RETINA; CAPILLARY PERMEABILITY; CULTURE TECHNIQUE; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOLOGY; WESTERN BLOTTING;

ADULT; AGED; APOLIPOPROTEIN B-100; APOPTOSIS; BLOTTING, WESTERN; CAPILLARY PERMEABILITY; CASPASE 3; CASPASE 7; CELL CULTURE TECHNIQUES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IN SITU NICK-END LABELING; LIPOPROTEINS, LDL; MACROPHAGES; MIDDLE AGED; OXIDATION-REDUCTION; PERICYTES; RETINA;

EID: 47249104206     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1440     Document Type: Article

References (49)

1. Gardner TW, Antonetti DA. A prize catch for diabetic retinopathy. Nat Med. 2007;13:131-132. (Pubitemid 46245757)
2. Cogan D, Toussaint D, Kuwabara T. Retinal vascular pattern, IV: diabetic retinopathy. Arch Ophthalmol. 1961;66:366-378.
3. Hammes HP, Lin J, Renner O, et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes. 2002;51:3107-3112.
4. Garner A. Histopathology of diabetic retinopathy in man. Eye. 1993;7:250-253. (Pubitemid 23153118)
5. Hammes HP. Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab Res. 2005;37:39-43.
6. Canning P, Glenn JV, Hsu DK, Liu FT, Gardiner TA, Stitt AW. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res. 2007;2007:51837. (Pubitemid 46630109)
7. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004;45:910-918. (Pubitemid 38868391)
8. Engerman RL. Pathogenesis of diabetic retinopathy. Diabetes. 1989;38:1203-1206. (Pubitemid 19247412)
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
10. Orchard TJ, Forrest KY, Ellis D, Becker DJ. Cumulative glycemic exposure and microvascular complications in insulin-dependent diabetes mellitus: the glycemic threshold revisited. Arch Intern Med. 1997;157:1851-1856. (Pubitemid 27381117)
11. The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicenter trial. N Engl J Med. 1984;311:365-372. (Pubitemid 14096746)
12. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes. 1987;36:808-812. (Pubitemid 17145301)
13. Klein R, Sharrett AR, Klein BE, et al. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the Atherosclerosis Risk in Communities Study. Ophthalmology. 2002;109:1225-1234. (Pubitemid 34700911)
14. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol. 2006;2:99-106. (Pubitemid 43239209)
15. Matsuura E, Kobayashi K, Tabuchi M, Lopez LR. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res. 2006;45:466-486. (Pubitemid 44331411)
16. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63:582-592. (Pubitemid 39078671)
17. Song W, Barth JL, Yu Y, et al. Effects of oxidized and glycated LDL on gene expression in human retinal capillary pericytes. Invest Ophthalmol Vis Sci. 2005;46:2974-2982. (Pubitemid 43086722)
18. Lyons TJ, Li W, Wells-Knecht MC, Jokl R. Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes. 1994;43:1090-1095. (Pubitemid 124005173)
19. Song W, Barth JL, Lu K, et al. Effects of modified low-density lipoproteins on human retinal pericyte survival. Ann N Y Acad Sci. 2005;1043:390-395. (Pubitemid 41123927)
20. Barth JL, Yu Y, Song W, et al. Oxidized, glycated LDL selectively influences tissue inhibitor of metalloproteinase-3 expression in human retinal capillary pericytes. Diabetologia. 2007;50:2200-2208. (Pubitemid 47373851)
21. Spranger J, Osterhoff M, Reimann M, et al. Loss of the anti-angiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes. 2007;50:2641-2645.
22. Kamat CD, Green DE, Warnke L, Thorpe JE, Ceriello A, Ihnat MA. Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Lett. 2007;249:209-219. (Pubitemid 46452929)
23. Vergès B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab. 2005;31:429-439. (Pubitemid 41639965)
24. Keiding NR, Mann GV, Root HF, Lawry EY, Marble A. Serum lipo-proteins and cholesterol levels in normal subjects and in young patients with diabetes in relation to vascular complications. Diabetes. 1952;1:434-440.
25. Duncan LJP, Cullen JF, Ireland JT, Nolan J, Clarke BF, Oliver MF. A three-year trial of Atromid therapy in exudative diabetic retinopathy. Diabetes. 1968;17:458-467.
26. Houtsmuller AJ. Treatment of exudative diabetic retinopathy with Atromid-S. Ophthalmologica. 1968;156:2-5.
27. Van Leiden HA, Dekker JM, Moll AC, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. Diabetes Care. 2002;25:1320-1325. (Pubitemid 41071139)
28. Lloyd CE, Klein R, Maser RE, Kuller LH, Becker DJ, Orchard TJ. The progression of retinopathy over 2 years: the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study. J Diabetes Complications. 1995;9:140-148.
29. Cusick M, Chew EY, Chan CC, Kruth HS, Murphy RP, Ferris FL. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology. 2003;110:2126-2133. (Pubitemid 37337848)
30. Gordon B, Chang S, Kavanagh M, et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol. 1991;112:385-391.
31. Lyons TJ, Patrick JS, Baynes JW, Colwell JA, Lopes-Virella MF. Glycation of low density lipoprotein in patients with type I diabetes: correlations with other parameters of glycaemic control. Diabetologia. 1986;29:685-689. (Pubitemid 17051036)
32. Ravandi A, Kuksis A, Shaikh NA. Glycosylated glycerophosphoethanolamines are the major LDL glycation products and increase LDL susceptibility to oxidation: evidence of their presence in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:467-477. (Pubitemid 30086105)
33. Pennathur S, Heinecke JW. Mechanisms for oxidative stress in diabetic cardiovascular disease. Antioxidants Redox Signaling. 2007;9:955-969. (Pubitemid 46919596)
34. Kruth HS, Shekhonin B. Evidence for loss of Apo B from LDL in human atherosclerotic lesions: extracellular cholesteryl ester lipid particles lacking Apo B. Atherosclerosis. 1994;105:227-234. (Pubitemid 24086513)
35. Tao Y, Kim J, Stanley M, et al. Pathways of caspase-mediated apoptosis in autosomal-dominant polycystic kidney disease (AD-PKD). Kidney Int. 2000;67:909-919.
36. Tsai JC, Jain M, Hsieh CM, et al. Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J Biol Chem. 1996;271:3667-3670. (Pubitemid 26065683)
37. Jenkins AJ, Velarde V, Klein RL, et al. Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes. 2000;49:2160-2169.
38. Hishita T, Tada-Oikawa S, Tohyama K, et al. Caspase-3 activation by lysosomal enzymes in cytochrome c-independent apoptosis in myelodysplastic syndrome-derived cell line P39. Cancer Res. 2001;61:2878-2884. (Pubitemid 32691929)
39. Gewies A, Rokhlin OW, Cohen MB. Cytochrome c is involved in Fas-mediated apoptosis of prostatic carcinoma cell lines. Cancer Res. 2000;60:2163-2168. (Pubitemid 30225179)
40. Chiu SM, Xue LY, Usuda J, Azizuddin K, Oleinick NL. Bax is essential for mitochondrion-mediated apoptosis but not for cell death caused by photodynamic therapy. Br J Cancer. 2003;89:1590-1597. (Pubitemid 37386619)
41. Cheng WC, Berman SB, Ivanovska I, et al. Mitochondrial factors with dual roles in death and survival. Oncogene. 2006;25:4697-4705. (Pubitemid 44187619)
42. Brady HJ, Gil-Gomez G. Bax: the pro-apoptotic Bcl-2 family member, Bax. Int J Biochem Cell Biol. 1998;30:647-650.
43. Podestà F, Romeo G, Liu WH, et al. Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro. Am J Pathol. 2000;156:1025-1032. (Pubitemid 30626960)
44. Li W, Liu X, He Z, Yanoff M, Jian B, Ye X. Expression of apoptosis regulatory genes by retinal pericytes after rapid glucose reduction. Invest Ophthalmol Vis Sci. 1998;39:1535-1543. (Pubitemid 28361313)
45. Saito Y, Geisen P, Uppal A, Hartnett ME. Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Mol Vis. 2007;13:840-853. (Pubitemid 46937860)
46. Lyons TJ, Li W, Wojciechowski B, Wells-Knecht MC, Wells-Knecht KJ, Jenkins AJ. Aminoguanidine and the effects of modified LDL on cultured retinal capillary cells. Invest Ophthalmol Vis Sci. 2000;41:1176-1180. (Pubitemid 30187557)
47. Yu Y, Li W, Wojciechowski B, Jenkins AJ, Lyons TJ. Effects of D-and L-glucose and mannitol on retinal capillary cells: inhibition by nanomolar aminoguanidine. Am J Pharmacol Toxicol. 2007;2:148-158.
48. Hughes JM, Kuiper EJ, Klaassen I, et al. Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia. 2007;50:1089-1098. (Pubitemid 46559257)
49. Yamato M, Matsumoto S, Ura K, et al. Are free radical reactions increased in the diabetic eye? Antioxid Redox Signal. 2007;9:367-373. (Pubitemid 46145982)